Market Closed -
Nasdaq
16:30:00 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
7.04
USD
|
-0.56%
|
|
+10.52%
|
-36.06%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,733
|
3,318
|
1,806
|
1,357
|
934.5
|
-
|
-
|
Enterprise Value (EV)
1 |
3,309
|
3,061
|
1,712
|
1,267
|
758.1
|
798
|
879.1
|
P/E ratio
|
-7.7
x
|
-8.04
x
|
-5.77
x
|
-3.95
x
|
-2.48
x
|
-2.49
x
|
-2.68
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
45.2
x
|
1,095
x
|
1,308
x
|
53.1
x
|
145
x
|
115
x
|
22.2
x
|
EV / Revenue
|
40
x
|
1,011
x
|
1,240
x
|
49.6
x
|
118
x
|
98.4
x
|
20.9
x
|
EV / EBITDA
|
-63.3
x
|
-8.55
x
|
-5.8
x
|
-3.45
x
|
-1.94
x
|
-2.05
x
|
-2.01
x
|
EV / FCF
|
-31.7
x
|
-39.3
x
|
-7.18
x
|
-4.16
x
|
-3
x
|
-3
x
|
-3.44
x
|
FCF Yield
|
-3.16%
|
-2.54%
|
-13.9%
|
-24%
|
-33.4%
|
-33.3%
|
-29.1%
|
Price to Book
|
4.9
x
|
3.7
x
|
1.76
x
|
1.79
x
|
1.3
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
89,811
|
108,044
|
120,895
|
123,269
|
132,742
|
-
|
-
|
Reference price
2 |
41.56
|
30.71
|
14.94
|
11.01
|
7.040
|
7.040
|
7.040
|
Announcement Date
|
21-03-25
|
22-02-24
|
23-02-23
|
24-02-22
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
82.65
|
3.029
|
1.381
|
25.55
|
6.423
|
8.114
|
42.05
|
EBITDA
1 |
-52.25
|
-357.9
|
-295.1
|
-367.7
|
-390.4
|
-390.1
|
-437.9
|
EBIT
1 |
-55.8
|
-361.9
|
-299.3
|
-373
|
-399.3
|
-408.1
|
-407.2
|
Operating Margin
|
-67.51%
|
-11,946.58%
|
-21,670.89%
|
-1,460.11%
|
-6,216.72%
|
-5,029.54%
|
-968.44%
|
Earnings before Tax (EBT)
1 |
-52.41
|
-363.9
|
-290.5
|
-342
|
-375.3
|
-390.7
|
-396.6
|
Net income
1 |
-230.2
|
-363.9
|
-290.5
|
-342
|
-377.6
|
-391.4
|
-403.7
|
Net margin
|
-278.51%
|
-12,012.94%
|
-21,036.13%
|
-1,338.66%
|
-5,879.41%
|
-4,823.79%
|
-960.21%
|
EPS
2 |
-5.400
|
-3.820
|
-2.590
|
-2.790
|
-2.836
|
-2.829
|
-2.624
|
Free Cash Flow
1 |
-104.4
|
-77.88
|
-238.6
|
-304.4
|
-253
|
-265.7
|
-255.6
|
FCF margin
|
-126.33%
|
-2,571.05%
|
-17,273.86%
|
-1,191.74%
|
-3,939.56%
|
-3,275.13%
|
-608.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-25
|
22-02-24
|
23-02-23
|
24-02-22
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.567
|
0.419
|
0.365
|
0.344
|
0.253
|
0.226
|
0.119
|
25.2
|
-
|
10.01
|
0.02
|
0.04
|
0.02
|
-
|
-
|
EBITDA
1 |
-65.85
|
-
|
-
|
-
|
-
|
-99.98
|
-104.7
|
-72.21
|
-90.82
|
-88.97
|
-98.27
|
-95.75
|
-93.16
|
-98.09
|
-100.5
|
EBIT
1 |
-66.89
|
-62.72
|
-77.81
|
-85.89
|
-72.85
|
-101.2
|
-106
|
-73.58
|
-92.2
|
-90.36
|
-102.5
|
-101.7
|
-101.1
|
-101.9
|
-104.3
|
Operating Margin
|
-11,796.65%
|
-14,969.21%
|
-21,318.08%
|
-24,968.6%
|
-28,794.86%
|
-44,768.58%
|
-89,117.65%
|
-291.95%
|
-
|
-903%
|
-512,534%
|
-254,325%
|
-505,487%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-67.46
|
-62.05
|
-76.79
|
-84.17
|
-67.5
|
-94.24
|
-98.5
|
-65.73
|
-83.5
|
-81.39
|
-95.9
|
-95.5
|
-95.16
|
-98.38
|
-100.3
|
Net income
1 |
-67.46
|
-62.05
|
-76.79
|
-84.17
|
-67.5
|
-94.24
|
-98.5
|
-65.73
|
-83.5
|
-81.39
|
-89.21
|
-96.84
|
-88.8
|
-100.3
|
-102.5
|
Net margin
|
-11,897%
|
-14,808.11%
|
-21,037.81%
|
-24,468.6%
|
-26,681.03%
|
-41,698.67%
|
-82,777.31%
|
-260.83%
|
-
|
-813.3%
|
-446,048.35%
|
-242,087.5%
|
-444,024.15%
|
-
|
-
|
EPS
2 |
-0.6200
|
-0.5700
|
-0.7100
|
-0.7600
|
-0.5600
|
-0.7800
|
-0.8100
|
-0.5400
|
-0.6700
|
-0.6200
|
-0.7347
|
-0.7278
|
-0.7242
|
-0.7000
|
-0.7133
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-02-24
|
22-05-05
|
22-08-04
|
22-11-03
|
23-02-23
|
23-05-04
|
23-08-08
|
23-11-02
|
24-02-22
|
24-05-02
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
423
|
257
|
94.1
|
90.3
|
176
|
137
|
55.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-104
|
-77.9
|
-239
|
-304
|
-253
|
-266
|
-256
|
ROE (net income / shareholders' equity)
|
-79%
|
-43.8%
|
-31.4%
|
-40.2%
|
-59.4%
|
-51%
|
-45.9%
|
ROA (Net income/ Total Assets)
|
-38.6%
|
-40.2%
|
-27.6%
|
-35.2%
|
-42.3%
|
-40%
|
-35.9%
|
Assets
1 |
596.4
|
904.1
|
1,054
|
971.9
|
892.2
|
978.1
|
1,124
|
Book Value Per Share
2 |
8.480
|
8.300
|
8.470
|
6.130
|
5.410
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-0.7800
|
-2.040
|
-2.450
|
-2.280
|
-1.920
|
-
|
Capex
1 |
1.93
|
3.47
|
9.06
|
4.13
|
7.12
|
5.06
|
5.1
|
Capex / Sales
|
2.34%
|
114.59%
|
656.19%
|
16.15%
|
110.85%
|
62.42%
|
12.12%
|
Announcement Date
|
21-03-25
|
22-02-24
|
23-02-23
|
24-02-22
|
-
|
-
|
-
|
Last Close Price
7.04
USD Average target price
22.69
USD Spread / Average Target +222.31% Consensus |
1st Jan change
|
Capi.
|
---|
| -36.06% | 935M | | +25.69% | 47.9B | | +46.90% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|